Keylika
Keylika, based in Walnut Creek, CA, is a healthcare company developing the world's first prescription iron patch to treat Iron Deficiency Anemia (IDA) without gastrointestinal side effects.
Company Overview
Keylika is a healthcare company based in Walnut Creek, CA, USA. The company operates in the therapeutics sub-industry, focusing on developing metal-based drugs to address unmet medical needs. It is part of the Y Combinator S22 batch and engages in fields including Medical Devices, Biotech, Nanotechnology, and Drug Discovery.
Innovative Therapeutic Solutions
Keylika is pioneering the development of metal-based drugs through a platform synthesis technology. Its first product is a small molecule iron drug designed for delivery via a wearable skin patch, aimed at treating Iron Deficiency Anemia (IDA). This product seeks to provide a solution for iron deficiency without the gastrointestinal side-effects commonly associated with oral iron supplements.
Market Position and Target Audience
Keylika targets a $17 billion US market with its first product. The company aims to address the iron deficiency problem, which impacts approximately 1.6 billion people globally and over 30 million individuals in the United States. The proprietary transdermal iron technology aims to be the world's first prescription iron patch upon regulatory approval.
Alternative to IV Iron Infusions
Keylika's innovative wearable skin patch for iron delivery serves as an alternative to traditional IV iron infusions. The product is designed to avoid the risks, costs, and side-effects associated with intravenous iron treatments. By utilizing proven delivery technologies, Keylika ensures optimal clinical outcomes for patients.
Global and Remote Operations
Keylika operates in various regions, including the United States, America/Canada, and in partly or fully remote settings. This flexible operational model allows the company to expand its reach and collaborate effectively across different geographical locations.